GlassScriptPhysician profile
Ashvini K Reddy
NPI 1417102476
$25,837.70
in general payments reported to CMS, 2019-2025
21 companies · $9,478 in 2025
The $9,478 reported for 2025 was more than what 80% of Uveitis and Ocular Inflammatory Disease providers received nationally (typical 2025 total: $471).
See the full distribution for Uveitis and Ocular Inflammatory Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $3,353 · 2021: $3,275 · 2022: $5,666 · 2023: $2,558 · 2024: $987 · 2025: $9,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $10K · Food and Beverage: $2,707 · Travel and Lodging: $41.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,275.00 |
| Food and Beverage | $2,706.71 |
| Travel and Lodging | $41.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $9,185.50 | 2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Alimera Sciences, INC. | $7,786.89 | 2019-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $3,356.51 | 2019-2023 | |
| Heidelberg Engineering, INC. | $2,263.86 | 2020-2021 | |
| Genentech USA, INC. | $597.17 | 2019-2024 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $589.70 | 2019-2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $494.23 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $471.94 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $175.71 | 2020 | |
| Genentech, INC. | $125.41 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $124.99 | 2023 | Eylea |
| Amgen INC. | $121.63 | 2024 | Tepezza |
| Abbvie INC. | $120.51 | 2023 | |
| Allergan, INC. | $109.11 | 2021 | |
| Alcon Vision LLC | $88.49 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $44.48 | 2023 | Cequa |
| Boston Scientific Corporation | $41.05 | 2020 | |
| Mallinckrodt Hospital Products INC. | $25.56 | 2025 | Acthar |
| Coherus Oncology, INC. | $24.00 | 2023 | |
| Apellis Pharmaceuticals, INC. | $21.20 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashvini Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.